ImmunoCellular Therapeutics to Present at Second Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference on Octob

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) ("ImmunoCellular" or the "Company") a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that the company will present at the Second Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference on October 6, 2011 at the New York Academy of Medicine in New York City. The conference will include panel discussions, keynote speakers, and presentations by various individuals and companies engaged in immunotherapeutic cancer research and development, as well as provide the opportunity for key opinion leaders, industry executives, and investors to engage in group and one-on-one discussions.

Manish Singh, Ph.D., President and CEO of ImmunoCellular Therapeutics, will present at the conference at 11:45 am EDT and will discuss the Phase II trial of ICT-107, the Company’s lead candidate for the treatment of glioblastoma.

A corresponding live webcast of the Company presentation will be accessible by visiting the Webcasts and Presentations under the "Investors" section of the IMUC website at www.imuc.com .

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, the risk that IMUC will not be able to secure a licensee for development and commercialization of ICT-107 on favorable terms or at all; the need for substantial additional capital to fund development of ICT-107 through to commercialization; the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials; the risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or that any patents covering this vaccine will provide commercially significant protection for this product candidate. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

ImmunoCellular Therapeutics, Ltd.
CEOcast, Inc.
James Young, 212-732-4300
Investor Relations
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology

MEDIA:

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.